2401 4TH AVE., SEATTLE, WA
Stockholder Meeting Results; Directors Zsolt Harsanyi and Barbara Lo Elected
Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
Annual Report to Security Holders
Other Events, Press Release
Secures $1.5 Million Non-Dilutive Research Grant from the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment at Closing
Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Q2
Q1
Q3
FY 2023
Notice of Exempt Offering of Securities
S-1
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
PRE 14A
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload